|
Report No. : |
334711 |
|
Report Date : |
05.08.2015 |
IDENTIFICATION DETAILS
|
Name : |
RANBAXY PHARMACEUTICALS INC. |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
28.10.2003 |
|
|
|
|
Legal Form : |
Corporation – Profit |
|
|
|
|
Line of Business : |
Subject is an integrated, research-based, international pharmaceutical
company that manufacturers a range of generic medicines |
|
|
|
|
No. of Employee : |
1,000 (for the group in
the |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with a per capita GDP of $54,800. In 2014, however, US GDP ran second to China’s, when compared on a Purchasing Power Parity basis; the US lost the top spot, where it had stood for more than a century. In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, they face higher barriers to enter their rivals' home markets than foreign firms face entering US markets. US firms are at or near the forefront in technological advances, especially in computers and in medical, aerospace, and military equipment; their advantage has narrowed since the end of World War II. The onrush of technology has been a driving factor in the gradual development of a "two-tier labor market" in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers, has put additional downward pressure on wages and upward pressure on the returns to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income. Imported oil accounts for nearly 55% of US consumption. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the United States into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression.
To help stabilize financial markets, in October 2008 the US Congress established a $700 billion Troubled Asset Relief Program (TARP). The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009 the US Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the federal government reduced the growth of spending and the deficit shrank to 7.6% of GDP. Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through 2014, the direct costs of the wars totaled more than $1.5 trillion, according to US Government figures. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries. In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform that was designed to extend coverage to an additional 32 million American citizens by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on health care - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010. In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight. In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. In late 2013, the Fed announced that it would begin scaling back long-term bond purchases to $75 billion per month in January 2014 and reduce them further as conditions warranted; the Fed ended the purchases during the summer of 2014. Long-term problems include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.
|
Source
: CIA |
RANBAXY
PHARMACEUTICALS INC.
9431 Florida Mining Blvd East, Jacksonville, FL 32257 - USA
Telephone: +1
904-470-6000
Fax: +1 904-880-9645
Website: www.ranbaxy.com
Corporate ID#: P03000121513
State: Florida
Judicial form: Corporation – Profit
Date incorporated: 10-28-2003
Stock: 100
shares common
Value: USD1=
par value
James MEEHAN
Business:
Ranbaxy Laboratories is an integrated, research-based, international
pharmaceutical company that manufacturers a range of generic medicines.
The company has more than 1,000 scientists who are engaged in research projetcs.
Ranbaxy Laboratories drug delivery systems focus on maximizing the
overall therapeutic and commercial value of prescribed pharmaceutical
formulations. The company s new drug discovery research program focuses on the
therapeutic segments of infectious, oncology, and inflammatory and respiratory
diseases. Ranbaxy Laboratories have operations in various countries, including
India, North America, Europe, Africa, Asia Pacific, Middle East and Sri Lanka.
The company manufactures and markets generic pharmaceuticals, branded generics,
active pharmaceuticals and intermediates.
Ranbaxy Laboratory’s anti-infectives
and dermatological products include simvastatin, amoxycillin and
ciprofloxacin.
Office of the Foreign
Assets Control (OFAC):
The company is not listed on the OFAC list.
The Specially Designated Nationals (SDN) List is a publication of OFAC
which lists individuals and organizations with whom United States citizens and
permanent residents are prohibited from doing business.
Foreign
suppliers include:
RANBAXY LABORATORIES LIMITED
12TH FLOOR,DEVIKA TOWER, 6 NEHRU PLACE, NEW DELHI 110019,INDIA
EIN: 16-1687539
Staff: 1,000 (for the group in the
U.S.)
Operations & branches:
At the headquarters, we
find a warehouse and office, on lease.
RANBAXY INC.
600 College Road E, Ste
2100, PO Box 8208, Princeton, NJ 08540
Founded in 1994, Ranbaxy Inc. offers various research and development
services, such as laboratory tests, clinical research, drug development,
in-licensing, promotion, distribution and marketing support solutions.
The company provides a range of tablets, caplets, capsules, laxatives,
antacids and analgesics for cough and cold, diabetes and skin treatments.
It offers products under the brand names of Proctosol, Riomet, Sotret,
Flomax and Cipro.
The company distributes its products in more than 125 countries
worldwide.
It is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India,
which manufactures a variety of generic and patented pharmaceuticals.
The ultimate parent company is
SUN PHARMACEUTICALS INDUSTRIES LTD.
India
James MEEHAN is the Manager.
David BRENNAN is Treasurer.
Eman AHMED-FAKHRY is Secretary.
Subsidiaries And partnership: None
In United States, privately
held corporations are not required to publish any financials.
On a direct call, nobody
accepted to answer our questions.
We sent a fax but no answer
received.
However, consolidate sales
estimate for year 2014 is excess of USD 1 billion.
The business is profitable.
Banks: US Bank
Legal filings
& complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts
summary (UCC):
File number: 201206504429
Date filed: 04-09-2012
Lapse date: 04-09-2017
Secured Party: U.S. Bank Equipment Finance
1310 Madrid Street, Marshall, MN 56258
File number: 201400759321
Date filed: 02-17-2014
Lapse date: 02-17-2019
Secured Party: U.S. Bank Equipment Finance
1310 Madrid Street, Marshall, MN 56258